Reference interval for albumin-adjusted calcium based on a large UK population by Schini, M, Hannan, FM, Walsh, JS, Eastell, R

Biochemical Markers of Bone Resorption Compared with Estimates of Bone Resorption from Radiotracer Kinetic Studies in Osteoporosis by Eastell, R, Colwell, A, Hampton, L, Reeve, J

Intrauterine programming of adult body composition. by Gale, C, Martyn, C, Kellingray, S, Eastell, R, Cooper, C

Surgically treated osteonecrosis and osteomyelitis of the jaw and oral cavity in patients highly adherent to alendronate treatment: a nationwide user-only cohort study including ov... by Eiken, P, Prieto-Alhambra, D, Eastell, R, Abrahamsen, B

Surgically treated osteonecrosis and osteomyelitis of the jaw and oral cavity in patients highly adherent to alendronate treatment by Abrahamsen, B, Eiken, P, Prieto-Alhambra, D, Eastell, R

Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study by Prieto Alhambra, D, Abrahamsen, B, Eiken, P, Eastell, R

Markers of bone turnover and disease status in prostate cancer by Hannon, R, Wells, J, Hamdy, F, Hoyle, N, Eastell, R

Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate--Danish National Register Based Cohort Study. by Pazianas, M, Abrahamsen, B, Eiken, P, Eastell, R, Russell, R

Bisphosphonates and colon cancer: reply. by Pazianas, M, Abrahamsen, B, Eiken, P, Eastell, R, Russell, R

Bisphosphonates and colon cancer: Reply by Pazianas, M, Abrahamsen, B, Eiken, P, Eastell, R, Russell, R

Esophageal and gastric cancer incidence and mortality in alendronate users. by Abrahamsen, B, Pazianas, M, Eiken, P, Russell, R, Eastell, R

The risk of oesophageal and gastric cancer incidence and mortality in alendronate users: National cohort study by Abrahamsen, B, Pazianas, M, Eiken, P, Russell, R, Eastell, R

Determinants of bone loss in elderly men and women: a prospective population-based study. by Dennison, E, Eastell, R, Fall, C, Kellingray, S, Wood, P, Cooper, C

International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine position on bone marker standards in osteoporosis. by Vasikaran, S, Cooper, C, Eastell, R, Griesmacher, A, Morris, H, Trenti, T, Kanis, J

VERTEBRAL FRACTURE RISK REDUCTION IS INDEPENDENT OF THE MAGNITUDE OF BMD CHANGE by Adachi, J, Cooper, C, Watts, N, Manhart, MD, Barton, I, Eastell, R

The value of bone turnover markers in the prediction of vertebral fracture in patients using oral glucocorticoids. by van Staal, T, Eastell, R, Barton, I, Rizzoli, R, Javaid, M, Cooper, C

The value of bone turnover markers in the prediction of vertebral fracture in patients using oral glucocorticoids. by van Staa, T, Eastell, R, Barton, I, Rizzoli, R, Javaid, M, Cooper, C

A novel EXT1 splice site mutation in a kindred with hereditary multiple exostosis and osteoporosis. by Lemos, M, Kotanko, P, Christie, P, Harding, B, Javor, T, Smith, C, Eastell, R, Thakker, R

Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate by Watts, N, Cooper, C, Lindsay, R, Eastell, R, Manhart, MD, Barton, I, van Staa, T, Adachi, J

Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater dec... by Watts, N, Cooper, C, Lindsay, R, Eastell, R, Manhart, MD, Barton, I, van Staa, T, Adachi, J